Santhera Pharmaceuticals Holding Ltd successfully placed CHF 60 million 5.00% convertible bonds due 2022. The convertible bonds will mature on 17 February 2022 at 100% of their principal amount unless previously redeemed, converted or repurchased and cancelled. The terms of the convertible bonds provide for a reset of the conversion price if the average share price during a period immediately prior to the first anniversary of the issue date falls below a reference share price. Bank am Bellevue AG and Kepler Cheuvreux SA acted as Joint Bookrunners in this transaction.
Bär & Karrer acted as legal advisor to the Joint Bookrunners. The team included Thomas U. Reutter, Daniel Raun, Annette Weber and Michael Schneitter (all Capital Markets) as well as Susanne Schreiber and Michael Abegg (both Tax).